Loading...

Alexa Fluor® 700 anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5_Alx700_020608
C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) Alexa Fluor® 700 (filled histogram) or rat IgG2a, κ Alexa Fluor® 700 isotype control (open histogram).
  • RM4-5_Alx700_020608
    C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) Alexa Fluor® 700 (filled histogram) or rat IgG2a, κ Alexa Fluor® 700 isotype control (open histogram).
Compare all formats See Alexa Fluor® 700 spectral data
Cat # Size Price Quantity Check Availability Save
100536 100 µg 172€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 700 under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor® 700 has a maximum emission of 719 nm when it is excited at 633nm / 635nm. Prior to using Alexa Fluor® 700 conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.


Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Red Laser (633 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Garber C, et al. 2019. Nat Neurosci. 1.802777778. PubMed
  2. Dolfi B, et al. 2022. Cell Rep. 39:110949. PubMed
  3. Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed
  4. Phares TW, et al. 2022. Front Pharmacol. 13:1029636. PubMed
  5. Wei J, et al. 2022. Cancer Prev Res (Phila). 15:285. PubMed
  6. Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed
  7. Sambandam A, et al. 2023. Heliyon. 9:e14238. PubMed
  8. Houlder E, et al. 2023. Nat Commun. 14:1863. PubMed
  9. Zhang YN, et al. 2023. Nat Commun. 14:1985. PubMed
  10. Wu SY, et al. 2022. Mol Cancer. 21:84. PubMed
  11. Minutti CM, et al. 2019. Immunity. 50:645. PubMed
  12. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  13. Singh S, et al. 2019. PLoS Pathog. 15:e1007460. PubMed
  14. Paprckova D, et al. 2022. Front Immunol. 13:1009198. PubMed
  15. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  16. Best SA, et al. 2018. Cell Metab. 27:935. PubMed
  17. Qiu F, et al. 2022. J Cancer. 13:2893. PubMed
  18. Ni P, et al. 2014. J Immunol . 193:1778. PubMed
  19. Sandborn WJ, et al. 2021. Gastroenterology. 161:1853. PubMed
  20. Lissner MM, et al. 2020. Elife. 9:00. PubMed
  21. Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed
  22. Soni C, et al. 2014. J Immunol. 193:4400. PubMed
  23. Mamedov MR, et al. 2018. Immunity. 48:350. PubMed
  24. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  25. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  26. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  27. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  28. Calcinotto A, et al. 2018. Nat Commun. 9:4832. PubMed
  29. Hanna CC, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  30. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  31. Jain RW, et al. 2018. Cell Rep. 25:3342. PubMed
  32. Chauveau L, et al. 2021. EMBO Rep. 22:e52447. PubMed
  33. Grioni M, et al. 2021. Blood Adv. 5:2817. PubMed
  34. Cosentino K, et al. 2022. Mol Cell. 82:933. PubMed
  35. Leclerc M, et al. 2019. Nat Commun. 10:3345. PubMed
  36. Altin J, et al. 2011. J Allergy Clin Immunol. 127:1277. PubMed
  37. Siegemund S, et al. 2015. PLoS One. 10:124661. PubMed
  38. Sadik A, et al. 2020. Cell. 1252:182. PubMed
  39. Nelson CE et al. 2019. Cell Rep. 28(12):3092-3104 . PubMed
  40. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  41. Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed
  42. Amezcua Vesely MC, et al. 2020. Cell. 178(5):1176-1188.e15.. PubMed
  43. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  44. Hendrikx S et al. 2019. Cell reports. 26(5):1227-1241 . PubMed
  45. Wong E, et al. 2015. J Immunol. 194:4130. PubMed
  46. Schulze B, et al. 2016. Pathog Dis. 74: ftw020. PubMed
  47. Regli IB, et al. 2020. Cell Reports. 31(10):107746. PubMed
  48. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
  49. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  50. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  51. Mykkänen O, et al. 2014. PLoS One. 9:114790. PubMed
  52. Song W, et al. 2022. Immunity. 55:290. PubMed
  53. Avgustinova A, et al. 2021. Cell Stem Cell. . PubMed
  54. Ito Y, et al. 2021. Cell Reports. 35(4):109052. PubMed
RRID
AB_493701 (BioLegend Cat. No. 100536)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 5    Revision Date: 10.10.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account